Executive Chairman, Board of Directors, Interim Chief Executive Officer
Michael Breen is an English qualified solicitor/attorney and was formerly the Managing Director of the Sports and Entertainment Division of Bank Insinger de Beaufort N. V., which is a wealth management organization and was part of BNP Paribas Group, one of the world's largest banks. The holding company Insinger de Beaufort Holdings S.A. was listed on the Luxembourg Stock Exchange. Mr. Breen was also a director and major shareholder of an affiliate of Insinger de Beaufort Holdings S.A.
Mr. Breen is a former senior equity partner in the 400+ partner and 50+ office law firm of Clyde & Co, whose head office is based in the City of London, England.
Gregory Berk, M.D.
President of Research & Development, Chief Medical Officer
Dr. Berk brings over 30 years of experience and expertise in oncology drug development across medicine, industry and academia. Prior to joining GT Biopharma, Dr. Berk was Chief Medical Officer of Celularity, where he was responsible for the company's oncology, infectious and degenerative disease programs. Previously, he served as Chief Medical Officer of Verastem; President, Chief Medical Officer, and Board Member of Sideris Pharmaceuticals; Chief Medical Officer of BIND Therapeutics, and Chief Medical Officer of Intellikine, which was acquired by Takeda/Millennium. Prior to his roles as Chief Medical Officer, Dr. Berk was Senior Vice President of Global Clinical Development at Abraxis BioScience, where he was responsible for the Company's overall clinical strategy, including efforts to expand the indications for its lead clinical program, Abraxane®, as well as oversee the clinical development of its clinical pipeline. Dr. Berk also served on the integration leadership team during the Celgene, $3.7 Billion acquisition of Abraxis in 2010.
Dr. Berk obtained his medical degree from Case Western Reserve University and completed his internship, residency, and fellowship in internal medicine, hematology, and medical oncology at the Weill Medical College of Cornell University and New York Presbyterian Hospital, where he also served as a faculty member from 1989-2004. During this time, Dr. Berk served as an investigator on several industry-sponsored and cooperative group oncology clinical trials, including the pivotal trials for Gleevec® and Avastin®.
Chief Financial Officer
Mr. Ohri, an accomplished accounting and finance executive brings to GT Biopharma over 25 years of management, finance and public accounting experience in working with Board of Directors, capital markets, independent auditors and attorneys. Mr. Ohri, served as CFO for multiple public companies began his career in public accounting as an auditor for PricewaterhouseCoopers and subsequently for Deloitte & Touche in excess of seven years. He is a licensed CPA and received his MBA with a concentration in Accounting and Finance from the University of Detroit. Prior to this appointment, he served as a management consultant advising both privately held and publicly traded companies in numerous sectors including biotech and pharmaceuticals. Prior to his role as a management consultant, Mr. Ohri served as the CFO and a member of the Board of Directors of ToughBuilt Industries, Inc., a NASDAQ listed company serving global markets.
Jeffrey S. Miller, M.D.
Consulting Chief Scientific Officer
Jeffrey S. Miller, MD, received a Bachelor of Science degree from Northwestern University in Evanston, Illinois and received his MD from Northwestern University School of Medicine. He completed an internship and residency in Internal Medicine at the University of Iowa in Iowa City. After completing a post-doctoral fellowship in Hematology, Oncology and Transplantation at the University of Minnesota, he joined the faculty in 1991. Dr. Miller is currently a Professor of Medicine at the University of Minnesota. He is the Deputy Director of the University of Minnesota Masonic Comprehensive Cancer Center. He has more than 20 years of experience studying the biology of NK cells and other immune effector cells and their use in clinical immunotherapy with over 170 peer-reviewed publications. He is a member of numerous societies such as the American Society of Hematology, the American Association of Immunologists, a member of the American Society of Clinical Investigation since 1999. He serves on the editorial board for Blood and is a reviewer for a number of journals and NIH grants.
Gavin Choy, PharmD, MBA
Chief Clinical Development Officer
Dr. Choy received his Doctor of Pharmacy from University of Southern California and completed residency training at the U.S. Department of Veteran Affairs. Dr. Choy also holds a Master of Business Administration focused on Health Care from the University of California, Irvine, Paul Merage School of Business. Dr. Choy has more than 20 years in the pharmaceutical and biotechnology industry with various executive leadership roles, including serving as a Chief Operating Officer at Apollomics, Inc. as well as President, CG Pharmaceuticals, Inc.
Stacy Herb, MPH, MBA
Senior Vice President, Portfolio Management
Ms. Herb has more than 20 years of biotechnology experience across a spectrum of roles including corporate development, strategy, sales, marketing, research, and project leadership. Ms. Herb was previously Senior Vice President, Global Project Leadership at Celularity Inc., where she managed the corporate portfolio including MSC, NK, and CAR-T cellular therapy programs. During her tenure, she facilitated multiple successful IND submissions, led corporate alliance activities, and established strategy and partnerships across the company's portfolio of programs. Prior to Celularity, Ms. Herb held various strategy, business development, research, and sales and marketing roles with increasing responsibility at Celgene Corporation and Wyeth-Ayerst. Ms. Herb holds a Master of Public Health from The Johns Hopkins University and a Master of Business Administration from The University of Houston.
Leslie Bransfield, PhD
Vice President of Chemistry, Manufacturing, Control and Pharmaceuticals Sciences
Dr. Bransfield has over 10 years of drug development experience in the biopharmaceutical industry working on therapeutics from the preclinical stage through Phase 3 and has worked in various leadership roles including Executive Director of Program and Data Analytics at Synspira Therapeutics and Director of Analytical Development at Allena Pharmaceuticals where she successfully managed technical programs, IND enabling studies, and CMC regulatory strategies. Dr. Bransfield received a B.S. degree in Chemistry from Lake Superior State University, earned a Ph.D. in Chemistry from The Johns Hopkins University and completed her post-doctoral fellowship at the National Institute of Standards and Technology.